COST-EFFECTIVENESS OF ETRANACOGENE DEZAPARVOVEC FOR THE TREATMENT OF HEMOPHILIA B

被引：0
|
作者：
Sarker, J. [1 ]
Moradi, A. [2 ]
Whittington, M. [2 ]
Tice, J. A. [3 ]
Herce-Hagiwara, B. [2 ]
Fahim, S. M. [2 ]
Chu, J. [3 ]
Agboola, F. O. [2 ]
Pearson, S. [2 ]
Rind, D. M. [2 ]
Walton, S. [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Inst Clin & Econ Review, Boston, MA USA
[3] UCST Sch Med, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE555
引用
收藏
页码：S160 / S161
页数：2
相关论文
共 50 条
  • [1] The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B
    Sarker, Jyotirmoy
    Tice, Jeffrey A.
    Rind, David M.
    Pearson, Steven D.
    Walton, Surrey M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (08): : 868 - 872
  • [2] Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
    Pipe, S. W.
    Leebeek, F. W. G.
    Recht, M.
    Key, N. S.
    Castaman, G.
    Miesbach, W.
    Lattimore, S.
    Peerlinck, K.
    Van der Valk, P.
    Coppens, M.
    Kampmann, P.
    Meijer, K.
    O'Connell, N.
    Pasi, K. J.
    Hart, D. P.
    Kazmi, R.
    Astermark, J.
    Hermans, C. R. J. R.
    Klamroth, R.
    Lemons, R.
    Visweshwar, N.
    von Drygalski, A.
    Young, G.
    Crary, S. E.
    Escobar, M.
    Gomez, E.
    Kruse-Jarres, R.
    Quon, D. V.
    Symington, E.
    Wang, M.
    Wheeler, A. P.
    Gut, R.
    Liu, Y. P.
    Dolmetsch, R. E.
    Cooper, D. L.
    Li, Y.
    Goldstein, B.
    Monahan, P. E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (08): : 706 - 718
  • [3] Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
    Anguela, Xavier M.
    High, Katherine A.
    BLOOD ADVANCES, 2024, 8 (07) : 1796 - 1803
  • [4] Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B
    Castaman, Giancarlo
    Coppens, Michiel
    Pipe, Steven W.
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (12) : 919 - 932
  • [5] Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States
    Yan, Songkai
    McDade, Cheryl
    Thiruvillakkat, Kris
    Rouse, Robert
    Sivamurthy, Krupa
    Wilson, Michele
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 758 - 765
  • [6] Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany
    Meier, Niklaus
    Fuchs, Hendrik
    Galactionova, Katya
    Hermans, Cedric
    Pletscher, Mark
    Schwenkglenks, Matthias
    PHARMACOECONOMICS-OPEN, 2024, 8 (03) : 373 - 387
  • [7] COST-EFFECTIVENESS IN TREATMENT OF SEVERE HEMOPHILIA
    SCHIMPF, K
    NIEDERBERGER, M
    HAEMOSTASIS, 1981, 10 : 185 - 187
  • [8] Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States
    Wilson, Michele
    McDade, Cheryl
    Thiruvillakkat, Kris
    Rouse, Robert
    Sivamurthy, Krupa
    Yan, Songkai
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (08): : 805 - 816
  • [9] Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)
    Sekayan, Tro
    Simmons, Dana H.
    von Drygalski, Annette
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (12) : 1173 - 1184
  • [10] First Real-World Experience Administering Etranacogene Dezaparvovec Gene Therapy for People with Hemophilia B
    Ryan, Matthew L.
    Miller, Andrea
    O'Hearn, Patrick
    Desai, Vidhi Parikh
    BLOOD, 2023, 142
12345